Alexandria Hammond
Stock Analyst at B of A Securities
(3.83)
# 698
Out of 5,044 analysts
17
Total ratings
66.67%
Success rate
8.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Maintains: Buy | $30 → $29 | $14.84 | +95.42% | 2 | Aug 25, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $54.00 | +18.52% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $652.91 | +76.13% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $24.29 | +2.92% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $24.70 | +61.94% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $86.58 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $813.53 | +22.92% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $186.60 | +1.82% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $118.50 | -7.17% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $42.60 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $147.86 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $225.14 | -8.95% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $421.60 | -64.42% | 1 | Apr 22, 2024 |
89bio
Aug 25, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $14.84
Upside: +95.42%
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $54.00
Upside: +18.52%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $652.91
Upside: +76.13%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $24.29
Upside: +2.92%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $24.70
Upside: +61.94%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $86.58
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $813.53
Upside: +22.92%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $186.60
Upside: +1.82%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $118.50
Upside: -7.17%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $42.60
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $147.86
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $225.14
Upside: -8.95%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $421.60
Upside: -64.42%